Abstract Details

Title Alzheimer CSF Biomarkers in Patients with HIV Associated Neurocognitive Disorder

Topic Aging and Dementia

Presentation(s) P03 - (-)

Poster/Presentation
Number 083

Objective

Background BACKGROUND: HAND is a prevalent neurological disorder found in HIV+ individuals with a wide spectrum including: asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV-associated dementia (HAD). Previous studies suggested that there may be characteristics CSF changes in HAND with AD biomarkers. In this study, we compared CSF A?42 and tau profiles in AD and in HAND, and assessed the diagnostic utility of the AD biomarkers in HAND.

Design/Methods DESIGN/METHODS: This cross-sectional study included 25 subjects diagnosed with HAND, 17 with probable AD, and 4 with no cognitive impairment (NCI). Measurement of CSF A?42, total tau (t-tau), and phosphorylated tau 191 (p-tau) levels were performed by ELISA assays (Innogenetics, Ghent, Belgium). Statistical comparisons were done using ANOVA.

Results RESULTS: AD subjects had lower CSF A?42 and higher t-tau and p-tau compared to both NCI and HIV+ groups (p<0.05, n=46), as expected. However, levels of these three markers were similar between NCI and HIV+ groups. Among HAND subtypes, the mean CSF A?42, t-tau, and p-tau are highest in HAD and lowest in ANI, but no statistical differences were detected between groups.

Conclusions CONCLUSIONS: Although there is a trend of higher CSF tau in HAND with more severe cognitive impairment, we fail to demonstrate significant differences between groups. CSF amyloid and tau may not be useful markers of HAND, but clearly differentiated AD from others.

Authors/Disclosures
Josephine Hoi Yan Lee PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Edward J. Cupler, MD, FAAN (King Faisal Specialist Hospital and Research Center)	Dr. Cupler has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Ging-Yuek R. Hsiung, MD, FAAN (University of British Columbia)	Dr. Hsiung has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Hsiung has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. The institution of Dr. Hsiung has received research support from CIHR. The institution of Dr. Hsiung has received research support from NIH. The institution of Dr. Hsiung has received research support from Eli Lilly. The institution of Dr. Hsiung has received research support from Biogen.

��ɫ��

��ɫ��